Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Archer-Daniels-Midland Co (ADM) vs Pfizer Inc (PFE) Price & Performance

Archer-Daniels-Midland CoTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Archer-Daniels-Midland Co vs Pfizer Inc — how do they compare? Archer-Daniels-Midland Co trades at $80.46 (market cap $38.79B), while Pfizer Inc trades at $26.63 (market cap $154.18B). The key difference: Pfizer Inc is far larger — about 4× Archer-Daniels-Midland Co's market cap, and Pfizer Inc pays the higher dividend (6.36%). Which is the better fit depends on your goals.

ADMPFE
Market Cap
$38.79B$154.18B
Sector
Consumer StaplesHealth
52-Week High
$87.32$28.56
52-Week Low
$56.00$23.60
Enterprise Value
$47.04B$205.67B
Dividend Yield
2.58%6.36%
Volume
29,869,932

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Archer-Daniels-Midland Co

ADM trades at $76.59, down 1.19% with a bearish technical signal despite recent earnings beats. The company raised its 2026 outlook after strong Q2 results driven by biofuels and crushing margins. Valuation appears reasonable with P/E of 20.93 and P/S of 0.45, though revenue has declined from $101.6B in 2022 to $80.3B in 2025. Analyst consensus is mixed with 33% buy ratings but a $88 price target suggesting 15% upside.

The stock offers value with solid dividends and improved cash flow, but faces execution risks and revenue pressure. Near-term catalysts include Q3 earnings and continued biofuels strength, while competitive pressures and margin compression remain concerns. The current price near support at $76 provides a potential entry point for long-term investors.

Pfizer Inc

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Archer-Daniels-Midland Co

Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.

Read more on ADM

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE